RESUMO
Purpose: Objective of this study is to develop; tablet- in- a capsule system, to deliver Atenolol 25mg and Glyburide 5mg in the hard gelatin capsule. In order to improve patient compliance and reduce problems associated with complex therapeutic regimen Atenolol [cardio-selective beta-blocker] and Glyburide [anti-diabetic; sulfonylurea] are commonly, prescribed to the diabetic hypertensive patient
Method: In present work six different formulations of Atenolol [AF1-AF6] and Glyburide [GF1-GF6] were prepared by direct compression method using Avicel, Lactose DC, Crospovidone and Magnesium Stearate in different proportions and encapsulated in hard gelatin shells. Post compression parameters i.e. weight variation, diameter variation, thickness variation, hardness variation,% friability, disintegration,% drug release were determined at different pH 1.2, 4.5 and 6.8, and subjected to dissolution profile comparison through similarity factor [f[2]]
Results: Stability studies were performed and shelf lives were calculated by R-Gui Stab R console 2.15.2 and determined to be 15and 27 months for Atenolol and Glyburide respectively. The percentage drug contents of Atenolol and Glyburide were estimated spectrophotometerically at 286nm and 314.7nm respectively. Formulations CF1-CF6 [encapsulated] were subjected to weight variation, disintegration and dissolution tests and subjected to model dependant analysis for dissolution studies. The simultaneous quantitation of Atenolol and Glyburide for content assay was done by HPLC method of analysis
Conclusion: formulation CF6 is showing highest coefficient of correlation values for all models applied. So we can conclude that the proposed system can improve patient compliance by increasing the ease of administration of two drugs together